After building momentum for weeks, congressional action on patent reform legislation is beginning to slow. The Senate Judiciary Committee has twice postponed markup of the bi-partisan PATENT Act in recent weeks. Reportedly, one reason behind the pause is a push by the pharmaceutical industry to include amendments that would limit the Patent and Trademark Office’s (PTO) authority to reevaluate the validity of issued patents at the request of third-parties that haven’t themselves been accused of infringement.
top of page
Recent Posts
See AllIn an op-ed published in DC Journal, United for Patent Reform co-chairs, Stephanie Martz and Chris Mohr, called for the Senate to oppose...
United for Patent Reform submitted comments to the United States Patent and Trademark Office expressing support for the patent office’s...
United for Patent Reform sent a joint letter today to the Senate Judiciary Committee stressing how harmful the Patent Eligibility...
bottom of page
Comments